Background The full complement of DNA mutations that are responsible for the
pathogenesis of acute myeloid leukemia (AML) is not yet known. Methods We used …

Most patients with acute myeloid leukaemia (AML) die from progressive disease after
relapse, which is associated with clonal evolution at the cytogenetic level,. To determine the …

Background The genetic alterations responsible for an adverse outcome in most patients
with acute myeloid leukemia (AML) are unknown. Methods Using massively parallel DNA …

Most mutations in cancer genomes are thought to be acquired after the initiating event,
which may cause genomic instability and drive clonal evolution. However, for acute myeloid …

by sound has been given by the author, x and Lighthill 2 has suggested that the author's
method might be applied to a beam of sound. This paper deals with the consequences of …

Acute myeloid leukaemia is a highly malignant haematopoietic tumour that affects about
13,000 adults in the United States each year. The treatment of this disease has changed …

Background Randomized trials have shown that the transplantation of filgrastim-mobilized
peripheral-blood stem cells from HLA-identical siblings accelerates engraftment but …

Background The myelodysplastic syndromes are a group of hematologic disorders that often
evolve into secondary acute myeloid leukemia (AML). The genetic changes that underlie …

Background The molecular determinants of clinical responses to decitabine therapy in
patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) are …

Therapy-related acute myeloid leukaemia (t-AML) and therapy-related myelodysplastic
syndrome (t-MDS) are well-recognized complications of cytotoxic chemotherapy and/or …